Regeneron Announces Odronextamab Receives EMA Filing Acceptance For Treatment Of Relapsed/Refractory Follicular Lymphoma And Diffuse Large B-cell Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals has announced that its drug, Odronextamab, has received filing acceptance from the European Medicines Agency (EMA) for the treatment of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.
August 17, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron's drug, Odronextamab, has received EMA filing acceptance, potentially opening up new markets in Europe for the treatment of certain lymphomas.
The EMA filing acceptance for Odronextamab is a positive development for Regeneron as it signifies regulatory progress and potential market expansion in Europe. This could lead to increased sales and revenue for the company, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100